PureTech Health PLC First Capital Markets Meeting

TIDMPRTC

PureTech Health PLC

19 January 2016

PureTech Health - First Capital Markets Meeting, London

Tuesday 10 May 2016

Boston, Massachusetts, January 19, 2016 - PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a cross-disciplinary healthcare company developing novel medicines to tackle fundamental healthcare needs in disruptive ways, announces its first Capital Markets Meeting as a London Listed Company. The Company will provide insight into its strategy, progress of the Company's operating companies, and insights into new areas of unmet medical need being explored.

The meeting will take place in London on Tuesday 10 May 2016 from 13.00-17.00 BST and will feature PureTech presenters including members of the Company's Board of Directors.

Presenters at the event include:

   --     Daphne Zohar, Co-Founder & CEO of PureTech 
   --     Joi Ito, Chairman of the Board of Directors of PureTech; Director of the MIT Media Lab

-- Raju Kucherlapati, PhD, Independent Non-Executive Director, Scientific Advisory Board Member of PureTech; Co-Founder of Millennium Pharmaceuticals and Abgenix

-- John LaMattina, PhD, Independent Non-Executive Director of PureTech; former President of Pfizer Global Research and Development

-- Marjorie Scardino, Senior Independent Director of PureTech; former CEO of The Economist and of Pearson plc, Chairman of the MacArthur Foundation Board

-- Ben Shapiro, MD, Co-Founder & Non-Executive Director of PureTech; former Executive Vice President of Research for Merck

   --     Christopher Viehbacher, Independent Non-Executive Director of PureTech; former CEO of Sanofi

-- Joseph Bolen, PhD, Entrepreneur-In-Residence, PureTech; former President and Chief Scientific Officer at Moderna Therapeutics and former Chief Scientific Officer and Global Head of Oncology Research at Millennium

   --     Marko Ahtisaari, CEO and Co-Founder of the Sync Project 
   --     Bernat Olle, PhD, CEO of Vedanta Biosciences 
   --     Jan Skvarka, President, CEO of Tal Medical 
   --     Eddie Martucci, PhD, CEO of Akili Interactive Labs 
   --     Additional members of the PureTech leadership team

Please confirm if you would like to attend to PureTech.Event@fticonsulting.com

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary healthcare company, developing innovative products that could improve the lives of billions of patients. PureTech has a pipeline of 12 operating companies, seven of which are "growth stage" with external validation including strategic partnerships, outside funding, proof-of-concept or peer review in prestigious scientific journals. PureTech also has a pipeline of ten "concept phase" initiatives resulting from review of more than 650 ideas annually. PureTech is focused on areas including immune and inflammatory disorders; cognitive and psychiatric disorders; diabetes and obesity; oncology; and infectious diseases, and has over 110 patents and patent applications. PureTech's leading team and board, along with an advisory network of more than 50 expert founder-scientists and advisors across multiple disciplines, gives PureTech access to potentially ground-breaking science and technological innovation. For more information, visit www.puretechhealth.com and connect with us on Twitter.

# # #

Enquiries:

 
 PureTech 
  Julie DiCarlo, Senior Vice President,    +1 617 226 
  Communications and Investor Relations     4819 
 FTI Consulting (Communications adviser 
  to PureTech) 
  Ben Atwell                               +44 (0) 20 
  Matthew Cole                              3727 1000

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGGURPGUPQPWR

(END) Dow Jones Newswires

January 19, 2016 02:00 ET (07:00 GMT)

Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024